Results 131 to 140 of about 24,654 (177)

Determinants of Abl kinase stability and drug binding thermodynamics: Role of regulatory domains and phosphorylation. [PDF]

open access: yesProtein Sci
Juárez-Barragán A   +5 more
europepmc   +1 more source

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells

open access: yesPterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
openaire   +1 more source

Model Mice for BCR/ABL-Positive Leukemias

Blood Cells, Molecules, and Diseases, 2001
p210bcr/abl is detected in almost all chronic myelogenous leukemia (CML) patients and a significant number of acute lymphoblastic leukemia (ALL) cases. It is generated by a reciprocal chromosomal translocation, t(9;22) (q34;q11), and the enhanced kinase activity of the protein is believed to be implicated in the pathogenesis of the diseases. To examine
H, Honda, H, Hirai
openaire   +2 more sources

Current and future management of Ph/BCR-ABL positive ALL

Expert Review of Anticancer Therapy, 2014
Following the introduction of targeted therapy with tyrosine kinase inhibitors (TKI) at the beginning of the past decade, the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved. Presently, the use of refined programs with first/second generation TKI's and chemotherapy together with
Elena, Maino   +6 more
openaire   +2 more sources

Management of Bcr–Abl-positive leukemias with dasatinib

Expert Review of Anticancer Therapy, 2007
Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized,
openaire   +2 more sources

Mechanisms of resistance to imatinib mesylate in Bcr-Abl–positive leukemias

Current Opinion in Oncology, 2002
The constitutive activity of the Bcr-Abl tyrosine kinase plays a critical role in the molecular pathogenesis of not only the chronic but also the accelerated and blastic phases of chronic myelogenous leukemia. Therefore, Bcr-Abl tyrosine kinase is a rational therapeutic target in all phases of chronic myelogenous leukemia.
Ramadevi, Nimmanapalli, Kapil, Bhalla
openaire   +2 more sources

Home - About - Disclaimer - Privacy